Comparison
CJC-1295 vs Ipamorelin
Two different ways to raise growth hormone
The key difference
CJC-1295 mimics growth-hormone-releasing hormone (GHRH). Ipamorelin acts on the ghrelin receptor. Both prompt the pituitary to release growth hormone, through different receptors.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | Long-acting GHRH analog | Growth hormone secretagogue |
| Evidence | Early human research | Early human research |
| Status | Not FDA-approved. | Not FDA-approved. |
| Also known as | — | — |
| Researched for | Muscle & body composition, Sleep | Muscle & body composition, Sleep |
| Evidence strength | Early human research | Early human research |
What else differs
- Because they act on different receptors, they are often discussed as a pair.
- Both have only small or early human studies, and neither is FDA-approved.
- CJC-1295 with DAC is engineered to stay active much longer than ipamorelin.
Bottom line
Different mechanisms aimed at the same hormone, with limited human data on either.
Read the research
CJC-1295 on PubMed →
Ipamorelin on PubMed →
Educational content, not medical advice. This page does not recommend or dose any substance. Compounds that are not FDA-approved have not been established as safe or effective in people.